Multimodal imaging guides surgical management in a preclinical spinal implant infection model

Abstract

KPF report that they are employees of PerkinElmer, a manufacturer of optical and PET imaging equipment. LSM reports that he has received grant support from MedImmune, Pfizer, Moderna Therapeutics, Regeneron Pharmaceuticals, and Boehringer Ingelheim and consulting fees from Integrated BioTherapeutics, related to Staphylococcus aureus vaccines and therapeutics. JMVD reports that he has filed a patent application (WO2015/088346) on the use of 1D9, which is owned by his employer University Medical Center Groningen. NMB reports that he has received consulting fees from Zimmer Biomet, Bonesupport, Daiichi Sankyo, and Onkos and that he is a board or committee member of the Musculoskeletal Tumor Society and Orthopaedic Research and Education Foundation.

Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection

“…Bacterial inocula were prepared following previously published protocols (53)(54)(55)(56)(57). In brief, Xen36 was isolated on kanamycin to select for purity and affirm possession of the kanamycin-resistance marker integral to the lux operon.…”

Preclinical Optical Imaging to Study Pathogenesis, Novel Therapeutics and Diagnostics Against Orthopaedic Infection

“…Romero Pastrana et al combined in vivo BLI and FLI imaging to demonstrate that a fluorescently labeled mAb (800CW‐labeled 1D9) directed against the immunodominant staphylococcal antigen A (IsaA) of S. aureus accumulated at the site of an MSSA (ALC2906) and MRSA (SAP231) skin and soft tissue infection. Interestingly, in a spine model of S. aureus (Xen36) OIAI, in vivo BLI and FLI imaging was combined to demonstrate that the 800CW‐labeled 1D9 mAb accumulated at the site of infection and also decreased the bacterial burden . Moreover, in this spine model of OIAI, the fluorescently labeled ID9 mAb bound to the S. aureus bacteria in vivo and could be detected and then surgically debrided using the Solaris Fluorescence Image‐Guided Surgery System (PerkinElmer).…”

“…Moreover, in this spine model of OIAI, the fluorescently labeled ID9 mAb bound to the S. aureus bacteria in vivo and could be detected and then surgically debrided using the Solaris Fluorescence Image‐Guided Surgery System (PerkinElmer). This approach of fluorescence image‐guided surgery thus enabled real‐time visualization of the extent of fluorescently‐labeled S. aureus ‐infected tissue for improved debridement . Such an approach might translate to clinical practice to help improve the debridement of infected tissue in patients with OIAI.…”

“…Interestingly, in a spine model of S. aureus (Xen36) OIAI, in vivo BLI and FLI imaging was combined to demonstrate that the 800CWlabeled 1D9 mAb accumulated at the site of infection and also decreased the bacterial burden. 56 Moreover, in this spine model of OIAI, the fluorescently labeled ID9 mAb bound to the S. aureus bacteria in vivo and could be detected and then surgically debrided using the Solaris Fluorescence Image-Guided Surgery System (Perki-nElmer). This approach of fluorescence image-guided surgery thus enabled real-time visualization of the extent of fluorescently-labeled S. aureus-infected tissue for improved debridement.…”

“…This approach of fluorescence image-guided surgery thus enabled real-time visualization of the extent of fluorescently-labeled S. aureus-infected tissue for improved debridement. 56 Such an approach might translate to clinical practice to help improve the debridement of infected tissue in patients with OIAI.…”